What’s New with Innocoll?

Innocoll and DURECT Announce U.S. launch of POSIMIR^®

Innocoll Announces Strategic Investment from Hillhouse Investment

Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression

Innocoll Announces Positive Topline Results for XARACOLL^® (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use

Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio

Innocoll Announces Successful Completion of Debt Refinancing

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR^® (Bupivacaine Solution)

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll^® (bupivacaine hydrochloride) Implant

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

Louis Pascarella Appointed Chief Executive Officer of Innocoll